Facilitated By

San Antonio Medical Foundation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to evaluate the efficacy and safety of CC-90001 in subjects with Non-Alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Inactive

The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis and explored in subjects with NASH and Stage 4 fibrosis

Collaborative Project
Clinical Care
Other
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.